Last reviewed · How we verify
NCT07318363
IGNITE-TX Phase III: (Identifying Individuals for Genetic Testing & Treatment) Intervention
Phase 3 trial testing IGNITE-TX program in Communication in 2,100 participants. Not yet recruiting.
1 April 2030
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 2,100 |
| Start date | 1 June 2026 |
| Primary completion | 1 April 2030 |
| Estimated completion | 1 April 2032 |
| Sites | 1 location across United States |
Drugs / interventions tested
- IGNITE-TX program
- Genetic Counseling and Testing
Conditions studied
- Communication — all drugs for Communication →
- Informed Decision-making — all drugs for Informed Decision-making →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Communication or Informed Decision-making. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial aims to implement and compare an evidence- and theory-based intervention strategy (IGNITE-TX Intervention) to support probands and their ARRs in family communication, informed decision-making, and navigation to CGT with standard of care, free genetic testing/counseling, and intervention with free genetic testing/counseling.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07318363
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Communication
Currently open trials in the same condition.
- NCT07303517 — AI-Driven Consent Simplification Study · recruiting
- NCT07215507 — Timing of Physician Rounds for Antepartum Patients · NA · recruiting
- NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
- NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting
- NCT07137377 — Assessing the Impact of Therapeutic Communication on Patients' Anxiety During Elective Cesarean Sections · NA · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07318363 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 6 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07318363.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing